Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 307

Similar articles for PubMed (Select 16822092)

1.

Risks versus benefits of different types of long-acting injectable antipsychotics.

McEvoy JP.

J Clin Psychiatry. 2006;67 Suppl 5:15-8. Review.

PMID:
16822092
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
4.

Review of treatments that can ameliorate nonadherence in patients with schizophrenia.

Kane JM.

J Clin Psychiatry. 2006;67 Suppl 5:9-14. Review.

PMID:
16822091
5.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
6.

Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.

Citrome L, Jaffe A, Levine J.

Schizophr Res. 2010 Jun;119(1-3):153-9. doi: 10.1016/j.schres.2010.02.1066. Epub 2010 Mar 26.

PMID:
20347267
7.

Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.

Turner M, Eerdekens E, Jacko M, Eerdekens M.

Int Clin Psychopharmacol. 2004 Jul;19(4):241-9.

PMID:
15201572
8.
9.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
10.
11.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
12.

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Masand PS, Gupta S.

Drugs Aging. 2003;20(15):1099-110. Review.

PMID:
14651433
13.

Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.

Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M.

J Clin Psychiatry. 2004 Apr;65(4):531-6. Erratum in: J Clin Psychiatry. 2004 Aug;65(8):1150.

PMID:
15119916
14.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.

Pharmacoeconomics. 2005;23 Suppl 1:35-47.

PMID:
16416760
15.

[The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].

Faludi G.

Neuropsychopharmacol Hung. 2005 Mar;7(1):22-7. Review. Hungarian.

PMID:
16167464
16.

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.

J Psychiatry Neurosci. 1994 Jul;19(4):254-64. Review.

17.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
18.

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, Essock SM; Schizophrenia Trials Network.

J Clin Psychiatry. 2012 May;73(5):669-75. doi: 10.4088/JCP.11m07074. Epub 2012 Mar 6.

19.

Choice of maintenance medication for schizophrenia.

Davis JM, Chen N.

J Clin Psychiatry. 2003;64 Suppl 16:24-33. Review.

PMID:
14680416
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk